Plain-English translation of NCT07021677 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medicine called daratumumab to help treat a type of blood cancer called T-acute lymphoblastic leukemia. The study focuses on patients whose cancer is in remission (no visible disease) but who still have tiny amounts of leukemia cells that doctors can detect in bone marrow using special blood tests. The medication works by targeting and attacking these leftover cancer cells.
Even when patients appear to be cancer-free after chemotherapy, tiny amounts of leukemia cells may remain and potentially cause the cancer to come back. This trial is exploring whether this new treatment can eliminate those hidden cancer cells and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You would receive daratumumab infusions as an additional treatment after completing your initial chemotherapy. The study involves regular clinic visits and bone marrow testing to see if the medication successfully eliminates the remaining leukemia cells. The trial is small, enrolling only about 18 adults, and your care team will closely monitor your response to the treatment and watch for any side effects.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
India